Federal Bid

Last Updated on 09 Jun 2012 at 8 AM
Special Notice
Frederick Maryland

Sole Source Study to Establish Timing of the reversal of coagulopathy following hemorrhagic shock using small volume 7.5% NaCl with Adenocaine Mg2+

Solicitation ID N3239812DOBSON
Posted Date 16 Apr 2012 at 7 PM
Archive Date 09 Jun 2012 at 5 AM
NAICS Category
Product Service Code
Set Aside No Set-Aside Used
Contracting Office Not Specified
Agency Department Of Defense
Location Frederick Maryland United states 21702
Point Of Contact Not Available
The Naval Medical Logistics Command (NMLC) intends to award a sole source contract under the authority of FAR 6.302-1 to Hibernation Therapeutics Pty Ltd; Queensland, Australia 4811, for the collaborative study with Naval Medical Research Center (NMRC), to establish the timing of the correction of coagulopathy using small volume 7.5% NaCl with Adenocaine Mg2+ following severe blood loss in the robust preclinical rat model of hemorrhagic shock. A mechanistic study using the ROTEM and multiplate Platelet functional analysis will be performed in a rat model of severe hemorrhagic shock which may have important battlefield and clinical applications. Studies will include plasma aPTT and PT clotting times, and whole blood ROTEM clotting and platelet functions. These studies will be conducted concurrently to test different, potentially effective small volume resuscitation strategies to not only raise mean arterial pressure into the permissive range but to correct the hypocoagulopathy that occurs accompanying shock and blood loss. A comprehensive understanding of the mechanisms of acute coagulopathy along with small volume resuscitation has far reaching practical battlefield applications and may fill an urgent military capability gap. Additionally, evaluation and characterization of the clotting mechanisms in the robust rat model of hemorrhagic shock will provide essential baseline data for translation into larger battlefield relevant models and human safety trials. The estimated value of the contract is $200,000.00. HT demonstrates a unique and innovative concept and a unique capability of the source to provide the particular research services proposed, as no other vendors are capable of performing this work due to the patent and proprietary nature of the medication used in the study. Based on these unique capabilities and the previous research accomplished, HT is the only institution capable of meeting the Government’s requirements. This Notice of Intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data, including cost, sufficient to determine capability. All capability statements received by the closing date of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. All capability statements received by 4:00 PM Eastern Time, 1 MAY 2012 will be considered by the Government. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to [email protected].
Bid Protests Not Available

Similar Past Bids

Pittsburgh Pennsylvania 08 Apr 2019 at 7 PM
Tennessee 31 Oct 2023 at 9 AM
Tennessee 06 Jan 2021 at 5 AM
Location Unknown 30 Oct 2012 at 4 PM
Location Unknown 22 May 2023 at 4 AM

Similar Opportunities

Location Unknown 09 Jul 2025 at 4 AM
Pennsylvania 26 Jul 2025 at 4 AM (estimated)
Pennsylvania 26 Jul 2025 at 4 AM (estimated)